New Study Shows Psychotherapies Prove Successful In Reducing Suicide and Self-Injury Attempts In Youths
2024年9月9日
Study published in the Journal of the American Academy of Child and Adolescent Psychiatry reports high remission rates in suicidal behavior among youths following with certain kinds of therapy
A study 新しいタブ／ウィンドウで開く in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP) 新しいタブ／ウィンドウで開く, published by Elsevier, found that a high percentage of youth will experience periods of remission and recovery of suicide attempts during and after treatment with dialectical behavior therapy (DBT). Rates of remission and recovery were higher for DBT than supportive therapy. These findings support DBT as a first line treatment for suicide prevention in youth.
The study analyzed data from 173 teens who were randomly assigned to receive 6 months of DBT or supportive therapy. Youth were followed for an additional 6 months after completing treatment. Suicide attempts and non-suicidal self-injury were measured every three months during treatment and follow-up.
The study demonstrated promising outcomes with over 70% of the youth reporting remission of suicide attempts at each treatment and follow up interval. DBT yielded significantly higher rates of remission than supportive therapy, with 83% of youth who received DBT reporting remission at 3-6 months and 86% at 9-12 months, as compared to 62% and 66% for supportive therapy. DBT recovery rates (remission across two or more 3-month intervals) were lower than remission rates (ranging from 58% to 74%), with lower rates for longer time periods. Percentages of remission and recovery for non-suicidal self-injury were lower than those for suicide attempts, across both types of treatment.
Suicide is the 2nd leading cause of death for 10–14-year-olds and the 3rd leading cause of death for 15–24-year-olds in the United States. Effective treatment approaches are urgently needed. Results suggest that DBT may reduce suicide risk in a high percentage of youth by leading to periods of remission of suicide attempts. Additional research is needed to increase the percentage of youth with sustained remission of suicide attempts over time, as well as to increase percentages of remission of non-suicidal self-injury.
Study author, Dr Michele Berk, associate professor of child and adolescent psychiatry at Stanford University says, “remission rates are commonly provided to patients and families for other life-threatening illnesses, but little is known about remission rates in response to suicide-focused treatments. This study provides patients and families with critical information needed to make decisions about treatment options.”
She adds, “Increasing the availability DBT is an important goal for youth suicide prevention.”
Notes for editors
The article is "Remission, Recovery, Relapse, and Recurrence Rates for Suicide Attempts and Nonsuicidal Self-Injury for Suicidal Youth Treated With Dialectical Behavior Therapy or Supportive Therapy," by Michele S. Berk, PhD, Robert Gallop, PhD, Joan R. Asarnow, PhD, Molly C. Adrian, PhD, Jennifer L. Hughes, PhD, MPH, Elizabeth McCauley, PhD(https://doi.org/10.1016/j.jaac.2024.01.012). It appears in Journal of the American Academy of Child & Adolescent Psychiatry, volume 63, issue 9(September 2024), published by Elsevier.
Copies of this paper are available to credentialed journalists upon request; please contact Michele S. Berk PhDat [email protected].
About JAACAP
Journal of the American Academy of Child and Adolescent Psychiatry 新しいタブ／ウィンドウで開く (JAACAP) is the official publication of the American Academy of Child and Adolescent Psychiatry. JAACAP is the leading journal focusing exclusively on today's psychiatric research and treatment of the child and adolescent. Published twelve times per year, each issue is committed to its mission of advancing the science of pediatric mental health and promoting the care of youth and their families.
The Journal's purpose is to advance research, clinical practice, and theory in child and adolescent psychiatry. It is interested in manuscripts from diverse viewpoints, including genetic, epidemiological, neurobiological, cognitive, behavioral, psychodynamic, social, cultural, and economic. Studies of diagnostic reliability and validity, psychotherapeutic and psychopharmacological treatment efficacy, and mental health services effectiveness are encouraged. The Journal also seeks to promote the well-being of children and families by publishing scholarly papers on such subjects as health policy, legislation, advocacy, culture and society, and service provision as they pertain to the mental health of children and families.
エルゼビアについて エルゼビアは、科学情報と分析を牽引するグローバル企業として、研究者や医療従事者が社会の利益のために科学を進歩させ、医療成果を向上させることを支援しています。我々は信頼できるエビデンスベースのコンテンツと高度なAI対応デジタルテクノロジーに基づくソリューションにより、インサイトと重要な意思決定を促進することでこれを実現しています。
エルゼビアは、140 年以上にわたり研究および医療コミュニティの活動を支援してきました。全世界で 2,500 人以上の技術者を含む 9,500 人の従業員がおり、重要な職務における研究者や、図書館員、アカデミックリーダー、資金提供者、政府機関、R&D 関連企業、医師、看護師、将来の医療従事者や教育者を支援することに従事してきました。2,900 誌以上の科学ジャーナルと代表的な参考文献には、Cell Press、The Lancet、Gray's Anatomy など、各分野の主要なタイトルを含みます。 エルゼビア・ファウンデーション 新しいタブ／ウィンドウで開くと共に、開発途上国および世界中の科学、研究、医療分野におけるインクルージョン＆ダイバーシティを推進するため、支援コミュニティと連携して活動しています。 エルゼビアは、プロフェッショナルおよびビジネス顧客向けの情報に基づく分析および意思決定ツールのグローバルプロバイダーである RELX 新しいタブ／ウィンドウで開くグループの一部です。業務内容やデジタルソリューション、コンテンツ詳細については、 www.elsevier.com/ja-jpをご参照ください。